Now showing items 283-302 of 655

    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thurlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Inhibitor, TA (2017-07)
    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thürlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG) (2017-07)
      BACKGROUND: A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy ...
    • Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. 

      López-Knowles, E; Gao, Q; Cheang, MC; Morden, J; Parker, J; Martin, LA; Pinhel, I; McNeill, F; Hills, M; Detre, S; Afentakis, M; Zabaglo, L; Dodson, A; Skene, A; Holcombe, C; Robertson, J; Smith, I; Bliss, JM; Dowsett, M (2016-01)
      Gene expression is widely used for the characterisation of breast cancers. Variability due to tissue heterogeneity or measurement error or systematic change due to peri-surgical procedures can affect measurements but is ...
    • Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. 

      Crusz, SM; Tang, YZ; Sarker, S-J; Prevoo, W; Kiyani, I; Beltran, L; Peters, J; Sahdev, A; Bex, A; Powles, T; Gerlinger, M (2016-11-14)
      BACKGROUND: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the ...
    • High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia 

      Milligan, DW; Kochethu, G; Dearden, C; Matutes, E; MacConkey, C; Catovsky, D; Grp, NCRIHS (BLACKWELL PUBLISHING, 2006-04)
      We report a high incidence of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) in patients entered into the Medical Research Council Chronic Lymphocytic Leukaemia-5 trial. Of 115 newly diagnosed patients treated ...
    • High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments. 

      Bartram, J; Goulden, N; Wright, G; Adams, S; Brooks, T; Edwards, D; Inglott, S; Yousafzai, Y; Hubank, M; Halsey, C (2018-03)
    • High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. 

      Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; Peckitt, C; Kilgour, E; Smith, NR; Geh, C; Rooney, C; Cutts, R; Campbell, J; Ning, J; Fenwick, K; Swain, A; Brown, G; Chua, S; Thomas, A; Johnston, SR; Ajaz, M; Sumpter, K; Gillbanks, A; Watkins, D; Chau, I; Popat, S; Cunningham, D; Turner, NC (2016-08)
      FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level clonal ...
    • High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. 

      Abubakar, M; Howat, WJ; Daley, F; Zabaglo, L; McDuffus, LA; Blows, F; Coulson, P; Raza Ali, H; Benitez, J; Milne, R; Brenner, H; Stegmaier, C; Mannermaa, A; Chang-Claude, J; Rudolph, A; Sinn, P; Couch, FJ; Tollenaar, RA; Devilee, P; Figueroa, J; Sherman, ME; Lissowska, J; Hewitt, S; Eccles, D; Hooning, MJ; Hollestelle, A; Wm Martens, J; Hm van Deurzen, C; Investigators, K; Bolla, MK; Wang, Q; Jones, M; Schoemaker, M; Broeks, A; van Leeuwen, FE; Van't Veer, L; Swerdlow, AJ; Orr, N; Dowsett, M; Easton, D; Schmidt, MK; Pharoah, PD; Garcia-Closas, M (2016-07)
      Automated methods are needed to facilitate high-throughput and reproducible scoring of Ki67 and other markers in breast cancer tissue microarrays (TMAs) in large-scale studies. To address this need, we developed an automated ...
    • A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders 

      Van Geet, C (2016-06)
      Inherited bleeding, thrombotic, and platelet disorders (BPDs) are diseases that affect similar to 300 individuals per million births. With the exception of hemophilia and von Willebrand disease patients, a molecular analysis ...
    • Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia - A comparative review 

      Osuji, N; Matutes, E; Catovsky, D; Lampert, I; Wotherspoon, A (LIPPINCOTT WILLIAMS & WILKINS, 2005-07)
      We review retrospectively the spleen histology in 8 patients with T-cell large granular lymphocyte (LGL) leukemia and 4 with T-cell prolymphocytic leukemia (T-PLL) to identify characteristic patterns of involvement and to ...
    • HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target. 

      Fok, JHL; Hedayat, S; Zhang, L; Aronson, LI; Mirabella, F; Pawlyn, C; Bright, MD; Wardell, CP; Keats, JJ; De Billy, E; Rye, CS; Chessum, NEA; Jones, K; Morgan, GJ; Eccles, SA; Workman, P; Davies, FE (2018-05-15)
      Purpose: Myeloma is a plasma cell malignancy characterized by the overproduction of immunoglobulin, and is therefore susceptible to therapies targeting protein homeostasis. We hypothesized that heat shock factor 1 (HSF1) ...
    • Human Coronavirus OC43 Associated with Fatal Encephalitis. 

      Morfopoulou, S; Brown, JR; Davies, EG; Anderson, G; Virasami, A; Qasim, W; Chong, WK; Hubank, M; Plagnol, V; Desforges, M; Jacques, TS; Talbot, PJ; Breuer, J (2016-08)
    • Human embryonic stem cells: A potential system for modeling infant leukemia harboring MLL-AF4 fusion gene 

      Greaves, M (2007)
      Infant acute lymphoblastic leukemia harboring the fusion oncogene MLL-AF4, which arises in utero during embryonic development, is characterized by its dismal prognosis and short latency. The mechanisms of transformation ...
    • Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. 

      Litchfield, K; Levy, M; Orlando, G; Loveday, C; Law, PJ; Migliorini, G; Holroyd, A; Broderick, P; Karlsson, R; Haugen, TB; Kristiansen, W; Nsengimana, J; Fenwick, K; Assiotis, I; Kote-Jarai, Z; Dunning, AM; Muir, K; Peto, J; Eeles, R; Easton, DF; Dudakia, D; Orr, N; Pashayan, N; UK Testicular Cancer Collaboration; PRACTICAL Consortium; Bishop, DT; Reid, A; Huddart, RA; Shipley, J; Grotmol, T; Wiklund, F; Houlston, RS; Turnbull, C (2017-07)
      Genome-wide association studies (GWAS) have transformed understanding of susceptibility to testicular germ cell tumors (TGCTs), but much of the heritability remains unexplained. Here we report a new GWAS, a meta-analysis ...
    • Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer. 

      Brough, R; Gulati, A; Haider, S; Kumar, R; Campbell, J; Knudsen, E; Pettitt, SJ; Ryan, CJ; Lord, CJ (2018-10)
      Although defects in the RB1 tumour suppressor are one of the more common driver alterations found in triple-negative breast cancer (TNBC), therapeutic approaches that exploit this have not been identified. By integrating ...
    • Identification of miRSNPs associated with the risk of multiple myeloma. 

      Macauda, A; Calvetti, D; Maccari, G; Hemminki, K; Försti, A; Goldschmidt, H; Weinhold, N; Houlston, R; Andersen, V; Vogel, U; Buda, G; Varkonyi, J; Sureda, A; Lopez, JM; Watek, M; Butrym, A; Sarasquete, ME; Dudziński, M; Jurczyszyn, A; Druzd-Sitek, A; Kruszewski, M; Subocz, E; Petrini, M; Iskierka-Jażdżewska, E; Raźny, M; Szombath, G; Marques, H; Zawirska, D; Chraniuk, D; Halka, J; Hove Jacobsen, SE; Mazur, G; Sanz, RG; Dumontet, C; Moreno, V; Stępień, A; Beider, K; Pelosini, M; Reis, RM; Krawczyk-Kulis, M; Rymko, M; Avet-Loiseau, H; Lesueur, F; Grząśko, N; Ostrovsky, O; Jamroziak, K; Vangsted, AJ; Jerez, A; Tomczak, W; Zaucha, JM; Kadar, K; Pérez, JS; Nagler, A; Landi, S; Gemignani, F; Canzian, F (2016-10-08)
      Multiple myeloma (MM) is a malignancy of plasma cells usually infiltrating the bone marrow, associated with the production of a monoclonal immunoglobulin (M protein) which can be detected in the blood and/or urine. Multiple ...
    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS; PRACTICAL consortium (2018-09-13)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...
    • Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. 

      Went, M; Sud, A; Försti, A; Halvarsson, B-M; Weinhold, N; Kimber, S; van Duin, M; Thorleifsson, G; Holroyd, A; Johnson, DC; Li, N; Orlando, G; Law, PJ; Ali, M; Chen, B; Mitchell, JS; Gudbjartsson, DF; Kuiper, R; Stephens, OW; Bertsch, U; Broderick, P; Campo, C; Bandapalli, OR; Einsele, H; Gregory, WA; Gullberg, U; Hillengass, J; Hoffmann, P; Jackson, GH; Jöckel, K-H; Johnsson, E; Kristinsson, SY; Mellqvist, U-H; Nahi, H; Easton, D; Pharoah, P; Dunning, A; Peto, J; Canzian, F; Swerdlow, A; Eeles, RA; Kote-Jarai, Z; Muir, K; Pashayan, N; Nickel, J; Nöthen, MM; Rafnar, T; Ross, FM; da Silva Filho, MI; Thomsen, H; Turesson, I; Vangsted, A; Andersen, NF; Waage, A; Walker, BA; Wihlborg, A-K; Broyl, A; Davies, FE; Thorsteinsdottir, U; Langer, C; Hansson, M; Goldschmidt, H; Kaiser, M; Sonneveld, P; Stefansson, K; Morgan, GJ; Hemminki, K; Nilsson, B; Houlston, RS; PRACTICAL consortium (2018-09-13)
      Genome-wide association studies (GWAS) have transformed our understanding of susceptibility to multiple myeloma (MM), but much of the heritability remains unexplained. We report a new GWAS, a meta-analysis with previous ...
    • Identification of neutral tumor evolution across cancer types. 

      Williams, MJ; Werner, B; Barnes, CP; Graham, TA; Sottoriva, A (2016-03)
      Despite extraordinary efforts to profile cancer genomes, interpreting the vast amount of genomic data in the light of cancer evolution remains challenging. Here we demonstrate that neutral tumor evolution results in a ...